Top

Antimicrobial Resistance & Infection Control

Published in:

Open Access 01-12-2017 | Short report

Novel antibiotic combinations proposed for treatment of Burkholderia cepacia complex infections

Authors: Omar M. El-Halfawy, Marwa M. Naguib, Miguel A. Valvano

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2017

Abstract

Effective strategies to manage Burkholderia cepacia complex (Bcc) infections in cystic fibrosis (CF) patients are lacking. We tested combinations of clinically available antibiotics and show that moxifloxacin-ceftazidime could inhibit 16 Bcc clinical isolates at physiologically achievable concentrations. Adding low dose of colistin improved the efficacy of the combo, especially at conditions mimicking CF respiratory secretions.

Waters V. New treatments for emerging cystic fibrosis pathogens other than pseudomonas. Curr Pharm Des. 2012;18:696–725.CrossRefPubMed

Reik R, Spilker T, Lipuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol. 2005;43:2926–8.CrossRefPubMedPubMedCentral

Medina-Pascual MJ, Valdezate S, Carrasco G, Villalon P, Garrido N, Saez-Nieto JA. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. 2015;21:150–6.CrossRefPubMed

Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis. 2002;8:181–7.CrossRefPubMedPubMedCentral

De Soyza A, Meachery G, Hester KL, Nicholson A, Parry G, Tocewicz K, Pillay T, Clark S, Lordan JL, Schueler S, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant. 2010;29:1395–404.CrossRefPubMed

Morrell MR, Pilewski JM. Lung transplantation for cystic fibrosis. Clin Chest Med. 2016;37:127–38.CrossRefPubMed

Stephenson AL, Sykes J, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Heart Lung Transplant. 2015;34:1139–45.CrossRefPubMed

Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;11:CD009876.PubMed

CLSI. Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. In: Wayne PA, editor. Clinical and Laboratory Standards Institute. 27th ed; 2017.

10.

Loutet SA, El-Halfawy OM, Jassem AN, Lopez JM, Medarde AF, Speert DP, Davies JE, Valvano MA. Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia. Int J Antimicrob Agents. 2015;46:376–80.CrossRefPubMed

11.

Selin C, Stietz MS, Blanchard JE, Gehrke SS, Bernard S, Hall DG, Brown ED, Cardona STA. Pipeline for screening small molecules with growth inhibitory activity against Burkholderia cenocepacia. PLoS One. 2015;10:e0128587.CrossRefPubMedPubMedCentral

12.

McClean S, Healy ME, Collins C, Carberry S, O'Shaughnessy L, Dennehy R, Adams A, Kennelly H, Corbett JM, Carty F, et al. Linocin and OmpW are involved in attachment of the cystic fibrosis-associated pathogen Burkholderia cepacia complex to lung epithelial cells and protect mice against infection. Infect Immun. 2016;84:1424–37.CrossRefPubMedPubMedCentral

13.

Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2007;51:1085–8.CrossRefPubMed

14.

Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2000;161:1206–12.CrossRefPubMed

15.

Van den Driessche F, Vanhoutte B, Brackman G, Crabbe A, Rigole P, Vercruysse J, Verstraete G, Cappoen D, Vervaet C, Cos P, et al. Evaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models. PLoS One. 2017;12:e0172723.CrossRefPubMedPubMedCentral

16.

Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, Vandamme P. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol. 2000;38:910–3.PubMedPubMedCentral

17.

El-Halfawy OM, Valvano MA. Chemical communication of antibiotic resistance by a highly resistant subpopulation of bacterial cells. PLoS One. 2013;8:e68874.CrossRefPubMedPubMedCentral

18.

CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—ninth edition. CLSI document M07-A9. In: Wayne PA, editor. Clinical and Laboratory Standards Institute; 2012.

19.

Vaara M, Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother. 1996;40:1801–5.PubMedPubMedCentral

20.

Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C, Hassett DJ, et al. Gene expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. J Med Microbiol. 2010;59:1089–100.CrossRefPubMed

21.

Quinn RA, Whiteson K, Lim YW, Salamon P, Bailey B, Mienardi S, Sanchez SE, Blake D, Conrad D, Rohwer FA. Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. ISME J. 2015;9:1024–38.CrossRefPubMed

22.

Falagas ME, Trigkidis KK, Vardakas KZ. Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: a systematic review. Int J Antimicrob Agents. 2015;45:221–33.CrossRefPubMed

23.

Lupo A, Isis E, Tinguely R, Endimiani A. Clonality and antimicrobial susceptibility of Burkholderia cepacia complex isolates collected from cystic fibrosis patients during 1998-2013 in Bern, Switzerland. New Microbiol. 2015;38:281–8.PubMed

24.

Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:5316–22.CrossRefPubMedPubMedCentral

25.

Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534–42.CrossRefPubMed

26.

Yapa SWS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother. 2014;58:2570–9.CrossRef

27.

Li J, Turnidge J, Milne R, Nation RL, Coulthard K. vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781–5.CrossRefPubMedPubMedCentral

28.

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601.CrossRefPubMed

29.

Hurley MN, Ariff AH, Bertenshaw C, Bhatt J, Smyth AR. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. Journal of cystic fibrosis: official journal of the European cystic fibrosis. Society. 2012;11:288–92.

30.

FDA Record on Avelox. 1999. [https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-085_Avelox_biopharmr.pdf].

31.

FDA Record on Fortaz. 2007. [https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf].

32.

Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. Journal of cystic fibrosis: official journal of the European cystic fibrosis. Society. 2017;16:492–5.

33.

Ratjen A, Yau Y, Wettlaufer J, Matukas L, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2015;59:711–3.CrossRefPubMed

Title: Novel antibiotic combinations proposed for treatment of Burkholderia cepacia complex infections
Authors: Omar M. El-Halfawy
Marwa M. Naguib
Miguel A. Valvano
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Antimicrobial Resistance & Infection Control / Issue 1/2017
Electronic ISSN: 2047-2994
DOI: https://doi.org/10.1186/s13756-017-0279-8

Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes

Open Access
Research

Key features of mcr-1-bearing plasmids from Escherichia coli isolated from humans and food

Open Access
Research

A twenty-four-hour observational study of hand hygiene compliance among health-care workers in Debre Berhan referral hospital, Ethiopia

Open Access
Research

Resistance of Staphylococcus aureus to antimicrobial agents in Ethiopia: a meta-analysis

Open Access
Research

Antibiotic resistance and biofilm formation among coagulase-negative staphylococci isolated from clinical samples at a tertiary care hospital of eastern Nepal

Open Access
Research

Prevalence and characteristics of ST131 clone among unselected clinical Escherichia coli in a Chinese university hospital

Open Access
Research

Keynote webinar | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content